Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 18/20 | 0.61 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | XDH | P47989 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2016897 | 1.00 | HSD11B1 (0.61) | HSD11B1EPHX2XDH | |
| SCHEMBL2016443 | 0.85 | HSD11B1 (0.72) | HSD11B1EPHX2 | |
| SCHEMBL1402850 | 0.76 | HSD11B1 (1.00) | HSD11B1 | |
| SCHEMBL1402697 | 0.70 | HSD11B1 (0.69) | HSD11B1EPHX2 | |
| SCHEMBL12268082 | 0.69 | HSD11B1 (0.70) | HSD11B1EPHX2 | |
| SCHEMBL1402714 | 0.67 | HSD11B1 (0.72) | HSD11B1 | |
| SCHEMBL1403226 | 0.67 | HSD11B1 (0.82) | HSD11B1EPHX2 | |
| SCHEMBL12268030 | 0.66 | HSD11B1 (0.72) | HSD11B1 | |
| SCHEMBL1402891 | 0.66 | HSD11B1 (0.72) | HSD11B1 | |
| SCHEMBL1402702 | 0.64 | HSD11B1 (0.64) | HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010123838-A2 | NOVEL AMIDE AND AMIDINE DERIVATIVES AND USES THEREOF | ABBOTT LABORATORIES (US) | 2010-10-28 | — | — | WO | claimed |
| EP-2243479-A2 | Novel amide and amidine derivates and uses thereof | Abbott Laboratories (US) | 2010-10-27 | — | — | EP | claimed |
| US-20100267738-A1 | NOVEL AMIDE AND AMIDINE DERIVATIVES AND USES THEREOF | ABBOTT LABORATORIES (US) | 2010-10-21 | — | — | US | claimed |
| US-8871208-B2 | 11-β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors and uses thereof | ABBVIE INC. (US) | 2014-10-28 | — | — | US | disclosed |
| US-8507493-B2 | Amide and amidine derivatives and uses thereof | ABBVIE INC. (US) | 2013-08-13 | — | — | US | disclosed |
| US-20110159005-A1 | 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 (11BETA-HSD1) INHIBITORS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2011-06-30 | — | — | US | disclosed |
| WO-2011068927-A2 | 11-β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 (11B-HSD1) INHIBITORS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2011-06-09 | — | — | WO | disclosed |
| WO-2010123838-A2 | NOVEL AMIDE AND AMIDINE DERIVATIVES AND USES THEREOF | ABBOTT LABORATORIES (US) | 2010-10-28 | — | — | WO | disclosed |
| EP-2243479-A2 | Novel amide and amidine derivates and uses thereof | Abbott Laboratories (US) | 2010-10-27 | — | — | EP | disclosed |
| US-20100267738-A1 | NOVEL AMIDE AND AMIDINE DERIVATIVES AND USES THEREOF | ABBOTT LABORATORIES (US) | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267738-A1 | NOVEL AMIDE AND AMIDINE DERIVATIVES AND USES THEREOF | HSD11B2, HSD11B1, HSD17B2 | HSD11B1 2/4885EPHX2 1112/4885XDH 1072/4885 |
| US-20110159005-A1 | 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 (11BETA-HSD1) INHIBITORS AND USES THEREOF | HSD11B1, HSD17B1, HSD11B2 | HSD11B1 1/4885EPHX2 661/4885XDH 211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.